Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on October 26, 2012, with the report date finalized on October 31, 2012. The filing addresses a specific corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a personnel change and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the resignation of a director:
- Resignation: Michael Sheffery, Ph.D., tendered his resignation from the Board of Directors, effective October 29, 2012.
- Reason: Dr. Sheffery was the designee of OrbiMed Advisors, LLC, an original investor. The resignation aligns with OrbiMed's policy of having representatives step down after a company becomes public.
- Board Action: The Board has not elected to fill the vacancy created by this resignation at this time.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific business risks. The only referenced document is a press release (Exhibit 99.1) detailing the resignation.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following Dr. Sheffery's departure.
- Confirm whether the Board intends to appoint a replacement for the vacant seat in the near future.
- Review the referenced Press Release (Exhibit 99.1) for any additional context regarding the resignation not included in the 8-K text.